250 related articles for article (PubMed ID: 29024572)
21. Identifying and managing the adverse effects of immune checkpoint blockade.
Winer A; Bodor JN; Borghaei H
J Thorac Dis; 2018 Feb; 10(Suppl 3):S480-S489. PubMed ID: 29593893
[TBL] [Abstract][Full Text] [Related]
22. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study.
Koelzer VH; Rothschild SI; Zihler D; Wicki A; Willi B; Willi N; Voegeli M; Cathomas G; Zippelius A; Mertz KD
J Immunother Cancer; 2016; 4():13. PubMed ID: 26981243
[TBL] [Abstract][Full Text] [Related]
23. [Adverse effects of immunotherapy : Clinical aspects, radiological and nuclear medicine results].
Widmann G; Nguyen VA; Plaickner J; Jaschke W
Radiologe; 2017 Oct; 57(10):840-849. PubMed ID: 28733704
[TBL] [Abstract][Full Text] [Related]
24. [Clinical practice and mechanism of endocrinological adverse events associated with immune checkpoint inhibitors].
Iwama S; Arima H
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):90-94. PubMed ID: 28603206
[TBL] [Abstract][Full Text] [Related]
25. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.
Makarious D; Horwood K; Coward JIG
Eur J Cancer; 2017 Sep; 82():128-136. PubMed ID: 28666240
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O
Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
[TBL] [Abstract][Full Text] [Related]
27. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
Kähler KC; Hauschild A
J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648
[TBL] [Abstract][Full Text] [Related]
28. A case report of orbital inflammatory syndrome secondary to ipilimumab.
Henderson AD; Thomas DA
Ophthalmic Plast Reconstr Surg; 2015; 31(3):e68-70. PubMed ID: 24814274
[TBL] [Abstract][Full Text] [Related]
29. Endocrine side effects of cancer immunotherapy.
Cukier P; Santini FC; Scaranti M; Hoff AO
Endocr Relat Cancer; 2017 Dec; 24(12):T331-T347. PubMed ID: 29025857
[TBL] [Abstract][Full Text] [Related]
30. Hypophysitis: Nursing Management of Immune-Related Adverse Events
.
Vazquez A
Clin J Oncol Nurs; 2017 Apr; 21(2):154-156. PubMed ID: 28315541
[TBL] [Abstract][Full Text] [Related]
31. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
Kaehler KC; Piel S; Livingstone E; Schilling B; Hauschild A; Schadendorf D
Semin Oncol; 2010 Oct; 37(5):485-98. PubMed ID: 21074064
[TBL] [Abstract][Full Text] [Related]
32. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
Boasberg P; Hamid O; O'Day S
Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
[TBL] [Abstract][Full Text] [Related]
33. Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities.
Gedye C; van der Westhuizen A; John T
Intern Med J; 2015 Jul; 45(7):696-701. PubMed ID: 25444021
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant immunotherapy: the sting in the tail.
Higham CE; Chatzimavridou-Grigoriadou V; Fitzgerald CT; Trainer PJ; Eggermont AMM; Lorigan P
Eur J Cancer; 2020 Jun; 132():207-210. PubMed ID: 32388064
[TBL] [Abstract][Full Text] [Related]
35. Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma.
Danlos FX; Pagès C; Roux J; Jebali M; Gornet JM; Bagot M; Lebbé C
Melanoma Res; 2015 Apr; 25(2):178-9. PubMed ID: 25464388
[TBL] [Abstract][Full Text] [Related]
36. Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy.
Narváez J; Juarez-López P; LLuch J; Narváez JA; Palmero R; García Del Muro X; Nolla JM; Domingo-Domenech E
Autoimmun Rev; 2018 Oct; 17(10):1040-1045. PubMed ID: 30103042
[TBL] [Abstract][Full Text] [Related]
37. Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors.
Kottschade LA
Curr Oncol Rep; 2018 Mar; 20(3):24. PubMed ID: 29511902
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
39. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
[TBL] [Abstract][Full Text] [Related]
40. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
